A short technical note on tirzepatide as a reference standard

Tirzepatide is a synthetic peptide reference standard in the dual-incretin-agonist class. This note summarizes the in-vitro evidence on its receptor-binding profile and is provided for laboratory researchers.

**Receptor binding.** The reference lyophilize has been characterized in cell-based receptor binding assays at the human GLP-1 receptor and the human GIP receptor, with a balanced binding profile across both receptors. The published in-vitro work shows picomolar-range binding affinity at both receptors and downstream cAMP signaling under controlled assay conditions.

**Use as a reference standard.** Researchers selecting tirzepatide for in-vitro incretin-receptor work should consult the lot-specific Certificate of Analysis for the documented HPLC purity, mass-spectrometry identity, and endotoxin levels. The catalog provides the reference standard in 10, 15, 20, 30, 50, and 100 mg lyophilized single-vial units.

**Selection of lot.** Each lot is documented and traceable. Researchers requiring matched lots for parallel protocols can request lot-reserved ordering from the research desk.

**All references cited in this note refer to in-vitro, ex-vivo, and preclinical animal-model work. No reference in this note should be read as evidence of human or veterinary applicability of any catalog product.**